Michael H. Cohen

Affiliated Counsel

Healthcare

What Are the OTC Drug Label Requirements?

August 23, 2025

By Michael H. Cohen

Over-the-counter (OTC) drugs are medications available without a prescription, intended to treat common health issues such as headaches, allergies, cold symptoms, or digestive discomfort. Under FDA regulations, OTC drug labels must follow a standardized drug facts format that includes active ingredients, purposes, directions, and more. 

In this article, we’re going to break down the importance of proper labeling for OTC drugs and walk you through the FDA’s specific OTC drug label requirements.

What Are OTC Drug Label Requirements?

OTC drug label requirements refer to the specific format and content standards that all over-the-counter (OTC) drug products must follow before being marketed to the public. These requirements ensure that the immediate container label, outer packaging, and any accompanying information provide consumers with clear, accurate, and complete details about the drug product’s purpose, uses, dosage, warnings, and ingredients. The applicable OTC drug monograph for each nonprescription drug product sets out what information must appear and in what form.

In the United States, the primary regulatory body responsible for overseeing OTC drug regulations is the U.S. Food and Drug Administration (FDA). The FDA enforces labeling provisions under the Federal Food, Drug, and Cosmetic Act (FD&C Act), which apply to all nonprescription drug products, topical drug products, and other OTC medicines.

Proper labeling is crucial for consumer safety because it communicates dosage warnings, separate allergy warnings, stomach bleeding warnings, sore throat warnings, and liver warnings, as well as other health risks that could necessitate immediate discontinuation of the drug. It is also essential for legal compliance, since products that do not meet OTC labeling format and content requirements may be considered misbranded and subject to enforcement action.

In summary, OTC drug labels must follow strict FDA rules on format, ingredients, warnings, and claims. A healthcare lawyer helps ensure compliance, advises on whether your product fits under an FDA monograph or needs special approval, and reviews marketing to avoid FTC violations. If the FDA challenges your labeling or advertising, a lawyer like those at Cohen Healthcare Law can guide your response, reduce risk, and keep your product legally on the market.

FDA Regulations on OTC Drug Labeling

The FDA uses the OTC drug monograph system to establish standardized requirements for drug product labeling without needing an approved drug application. Each relevant OTC drug monograph details the active ingredient, labeling requirements, proper dosage, and necessary warnings, including specific alerts such as warnings for asthma or for pregnant users based on their trimester.

The FDA requires a mandatory drug facts labeling format for all OTC medicines. This includes distinct headings, horizontal barlines, and consistent horizontal line spacing between sections.

Certain warnings, such as a liver warning or asthma alert warning, must appear in a box and in red letters to ensure visibility. Labeling must also follow the standardized format and content requirements, which include how the drug facts labeling appears on the package, the subsequent panel immediately following the first, and the proper placement of additional bulleted statements appearing under the appropriate heading.

Under the FD&C Act, drug product labeling must also meet packaging techniques intended to protect the drug from undergoing chemical change and to ensure that the dosage unit stated remains accurate. The FDA distinguishes between OTC and prescription drug labeling requirements. Prescription drug labels are tailored for healthcare professionals, whereas OTC medicine labels are designed for direct consumer use with complete instructions for safe self-administration.

What Information Is Required on an OTC Drug Label?

One of the requirements of an OTC drug label is the drug facts panel. This panel should include:

  • Active ingredients—The common or usual name and the appropriate dosage unit for each.
  • Purpose of the drug—The principal intended actions, such as pain relief, cough suppression, or fever reduction.
  • Uses—Conditions or symptoms the drug product is marketed to treat.
  • Warnings—This includes allergy alerts, separate allergy warnings, stomach bleeding warnings, sore throat warnings, dosage warnings, and any statement that would necessitate immediate discontinuation of the product. Special provisions may include an asthma alert warning set or a complete additional bulleted statement for conditions like liver damage risk.
  • Directions for use—The dosage directions for each age group should be stated in discrete dosage units and in the same line as other dosing instructions.
  • Other information – Storage instructions, inactive ingredients, and any toll-free number to report complaints.

There should also be a product identity, which must be clear on the principal display panel. It should include the name of the drug, the net quantity of contents, and any statement required by the applicable OTC drug monograph or proposed labeling provisions.

Additionally, there should be the manufacturer’s information. This must list the name and address of the manufacturer, packer, or distributor, either on the principal display panel or on such an exterior container as the immediate container label.

Can OTC Drug Label Requirements Vary by Country?

Yes, OTC drug regulations and labeling provisions vary significantly across countries. While the U.S. FDA has strict rules for how drug facts should be labeled, other countries might have different requirements, like needing extra warnings about sexually transmitted diseases or disclaimers for spermicide products. Some regions may require the same line formatting rules as the U.S., while others allow more than one statement or more than one panel for drug facts content.

These differences create challenges for international distribution because a drug product marketed in one country may need changes to meet another country’s format and content requirements. For example, certain allergy alert or dosage warning statements that are optional in one country might be mandatory in another.

Manufacturers distributing OTC medicines globally must study each applicable OTC drug monograph, adjust packaging techniques intended for different markets, and ensure that both the immediate container label and the subsequent horizontal line layouts comply with each jurisdiction’s rules. Strategic compliance planning and consultation with regulatory experts can help ensure smooth market entry without costly relabeling or product holds.

What Are the Consequences of Not Following OTC Drug Label Requirements?

Failure to comply with OTC drug label requirements can trigger serious legal and financial repercussions for any company marketing an over-the-counter (OTC) drug. Under the Federal Food, Drug, and Cosmetic Act, an OTC drug product that fails to meet the applicable OTC drug monograph or that does not display required information in the mandated OTC labeling format may be considered “misbranded.” This can result in product recalls, seizure of goods, injunctions, or civil penalties.

Beyond fines and legal sanctions, companies risk losing consumer trust and damaging brand reputation. OTC medicine labels are designed to help consumers safely use nonprescription drug products without medical supervision, and if a label’s drug facts, dosage warning, or dosage directions are inaccurate, it could lead to adverse events, hospitalizations, or even fatalities. For example, a drug product marketed without the appropriate dosage unit or with incomplete additional bulleted statements appearing under the appropriate heading could necessitate immediately discontinuing use and generate public backlash.

How to Ensure Compliance with OTC Drug Label Requirements

Compliance begins with strong internal review and quality control processes. Every OTC drug product, whether a topical drug product or oral medication, must be checked against the applicable OTC drug monograph and other OTC drug regulations to ensure all mandatory statements are present. This includes verifying that the drug facts labeling appears in the proper order, using horizontal barlines and the same horizontal line spacing, and that the subsequent panel immediately follows the first panel with no omissions.

Working with regulatory consultants or legal experts who specialize in OTC drug regulations can help companies navigate complex labeling provisions and packaging techniques intended to prevent the drug from undergoing chemical change. Periodic updates and audits are also essential, especially when format and content requirements change or when a modified form intended for a specific market must be adopted. Global distribution may require more than one panel or more than one statement to satisfy labeling provisions in other jurisdictions.

Furthermore, the use of specialized labeling software and tools can ensure that every immediate container label and outside container meets FDA standards. This includes properly displaying the common or usual name, net quantity, inactive ingredients, and a toll-free number for reporting complaints. Software can assist in applying the correct format without errors when an approved drug application necessitates a different layout.

Finally, hiring a healthcare lawyer is important. Your healthcare lawyer guides you through every stage of compliance, from reviewing your proposed labeling to helping you respond to FDA inquiries. They ensure your drug product labeling stays fully compliant and your brand remains protected.

How Do OTC Drug Label Requirements Differ from Prescription Drug Labels?

While both OTC drug label requirements and prescription drug labeling are regulated under the Federal Food, Drug, and Cosmetic Act, their regulatory standards differ in important ways. Over-the-counter (OTC) drug products are governed by the applicable OTC drug monograph or, in some cases, by an approved drug application. These regulations mandate the standardized Drug Facts labeling format, which dictates how the drug facts labeling appears, the placement of horizontal barlines, the same horizontal line spacing between sections, and the use of boxed statements.

Prescription drug labels, on the other hand, are not formatted with the same consumer-friendly drug facts panel. Instead, they follow a detailed package insert format intended primarily for healthcare professionals. This means that the principal intended actions, dosage directions, stated dosage units, and potential interactions are explained in medical language, often requiring prior diagnosis and professional interpretation. In prescription labeling, the healthcare provider serves as the intermediary, interpreting the drug product labeling and instructing patients on safe use, whereas OTC medicines must provide all necessary directions directly to the consumer.

OTC labeling requirements also focus heavily on immediate consumer comprehension, with the principal display panel, net quantity, active ingredient, inactive ingredients, and toll-free number for complaints clearly visible on the immediate container label and outside the container. Prescription labels rely more on pharmacist counseling, making consumer accessibility and the level of detail presented in OTC medicine labels a distinct regulatory and design challenge.

How OTC Drug Label Requirements Affect Consumers and Manufacturers

For consumers, well-designed OTC medicine labels deliver clear and accurate information needed to use nonprescription drug products safely without a doctor’s supervision. Compliance with the applicable OTC drug monograph ensures that dosage warnings, appropriate dosage units, and other required statements are present. This improves safety by alerting users to conditions that would necessitate immediate discontinuation of use, such as severe allergic reactions or adverse effects tied to liver damage, as communicated through a separate allergy warning or liver warning.

For manufacturers, OTC drug regulations carry both legal and financial implications. Failing to follow the OTC labeling format, omitting required statements, or using an improperly modified form intended for a specific market can render a drug product marketed in violation of FDA labeling provisions.

This could trigger recalls, fines, or even prevent the product from entering new markets, particularly where more than one statement or more than one panel is required under other OTC drug regulations abroad. Packaging techniques intended to preserve stability and prevent the product from undergoing chemical change are also closely scrutinized.

From a marketing perspective, OTC drug label requirements influence how brands design their principal display panel and overall packaging. The format and content requirements dictate the exact placement of the active ingredient, principal intended actions, and net quantity, while maintaining compliance with spacing rules like the subsequent horizontal line or horizontal barline immediately preceding each section.

Where Can I Find an OTC Label Template?

Finding a reliable OTC label template is essential for creating compliant over-the-counter (OTC) drug product packaging that meets FDA format and content requirements. The U.S. Food and Drug Administration provides sample label illustrations and guidance documents showing how drug facts labeling appears.

This includes the proper OTC labeling format, a horizontal barline immediately preceding each section, the same horizontal line spacing, and the placement of mandatory warnings like the asthma alert, sore throat warning, stomach bleeding warning, liver warning, and separate allergy warning. These resources, along with the applicable OTC drug monograph, help manufacturers design labels that include the active ingredient, the appropriate dosage unit, the stated dosage unit, the principal intended actions, the dosage warning, and all additional bulleted statements appearing under the appropriate heading.

For companies seeking efficiency, several regulatory compliance vendors and labeling software platforms offer downloadable OTC medicine labels in editable formats. These templates can be customized to match the principal display panel size, net quantity, immediate container label specifications, and other OTC drug regulations.

Customization is important because each nonprescription drug product is likely to have unique requirements under its OTC drug monograph. They might include special packaging methods to keep the drug stable, multiple panels for different languages, or a different design for specific topical or spermicide products.

In addition, working with a healthcare lawyer or regulatory consultant ensures that your customized label follows the correct format and content requirements, bears the labeling means as required, and includes every mandated element, from the toll-free number to report complaints to the inactive ingredients listing. At Cohen Healthcare Law Group, we can help review your proposed labeling to ensure compliance before your drug product is marketed, avoiding costly redesigns or enforcement action.

Want to Ensure OTC Drug Label Compliance?

OTC drug label requirements are set by the FDA to ensure that over-the-counter (OTC) drug products give consumers the information they need to use them safely and effectively. Proper OTC medicine labels must clearly show the main uses, amount of product, inactive ingredients, and a toll-free number on both the main container and any outer packaging. Compliance with these requirements protects public safety, prevents misuse, and shields manufacturers from legal and financial risks. 

FAQ

When it comes to over-the-counter (OTC) drug labeling, the rules are strict to ensure consumer safety. Below are answers to some of the most common questions about OTC drug labeling compliance:

What Are the FDA Requirements for OTC Drugs?

The FDA requires OTC drug products to follow the applicable OTC drug monograph or obtain an approved drug application. The drug facts label must be presented in a standardized format and include specific content, such as the active ingredient, dosage unit, uses, warnings, and directions. Labels must also meet format and content requirements under the Federal Food, Drug, and Cosmetic Act.

Can OTC Drug Labels Be Changed Without FDA Approval?

If the change is consistent with the applicable OTC drug monograph and maintains compliance with all OTC drug regulations, FDA pre-approval is generally not required. However, changes that alter active ingredients, principal intended actions, or safety warnings may necessitate additional review.

How Often Do OTC Drug Labels Need to Be Reviewed?

Manufacturers should review OTC medicine labels periodically to ensure they meet current FDA labeling provisions and reflect any updates to the OTC drug monograph. Reviews are also essential when new safety data emerges or when packaging techniques are intended for stability changes.

What Penalties Exist for Non-compliance With Labeling Requirements?

Non-compliance can lead to product recalls, fines, injunctions, or seizure of goods, and in severe cases, legal action for misbranding under the FD&C Act. These penalties can damage both consumer trust and brand reputation.

Are There Specific Font Size and Style Requirements for OTC Drug Labels?

Yes, the FDA’s OTC labeling format rules specify minimum font sizes, easy-to-read type styles, and spacing, along with horizontal barlines and the same horizontal line separation between sections. Certain warnings, like a liver warning or asthma alert warning set, may also require a box and red letters for emphasis.

What Are the Three Criteria That Must Be Met by an OTC Drug?

An OTC drug must be safe and effective for self-use without medical supervision, have labeling that provides clear drug facts and dosage directions, and contain active ingredients recognized as safe and effective under the applicable OTC drug monograph.

Categories: Healthcare

Related People

Related Services

  • Biography
  • Representative Matters
  • Blog Feed
  • Publications
  • News
  • Contact Michael

Firm Highlights

  • Events
    The 2026 Economic, Tax, and Accounting Updates
    We are looking forward to the Mid-Atlantic CFO Roundtable's next event on November 13, 2026. This is a program with topics built for Finance Executives. We are extremely fortunate to have three excellent speakers: Dr. Daraius Irani, Vice President of Business and Public Engagement at Towson University; Mike Stankus, Tax Office Managing Principal at BDO; and Daniel Wahlberg, Managing Partner of Acclare Solutions. The economy is rapidly changing with various factors driving it. The November 3rd midterm elections may also have an impact. Our three expert presenters will discuss the ramifications of the election, and the current year updates to GAAP financial reporting and Federal and State income taxes. Please join us for what will surely be an informative and timely discussion. Meet Our Speakers: Daraius Irani, Ph.D. • Towson University Vice President, Business & Public Engagement Dr. Daraius Irani serves as Vice President of Business and Public Engagement at Towson University as well as the chief economist for the Regional Economic Studies Institute (RESI) at Towson University, a policy group providing economic, fiscal impact, and policy analysis to public and private entities.  Dr. Irani is often called upon to provide economic presentations to organizations across Maryland. He has appeared on numerous television programs and in local and regional print media. Dr. Irani holds a Ph.D. in economics from University of California, Santa Barbara. Dan Wahlberg • Acclare Solutions Managing Partner With over 28 years of experience, Dan Wahlberg is a recognized leader in audit and assurance for the Mid-Atlantic’s middle market business community. As a licensed CPA in Maryland and Virginia, Dan has led assurance practices at top regional firms, including serving as Baltimore Audit Managing Partner and Assurance Practice Leader at BDO USA in Baltimore and as Partner and member of the Management Committee at Hertzbach & Company P.A which merged into BDO in 2020. His expertise centers on delivering clarity, strategic guidance, and proactive solutions to middle-market businesses across Baltimore and beyond. His entrepreneurial spirit has led him to begin a new CPA firm this year with four other CPAs serving the business community. Dan holds a Bachelor of Science in Accounting from Rutgers University and began his career at PWC in New York. He is also deeply engaged in the community, previously serving as President of ACG Maryland and current Board member and as Audit Committee Member for The Associated: Jewish Federation of Baltimore.  Mike Stankus • BDO USA LLP Tax Office Managing Principal Mike Stankus is the Tax Office Managing Principal for the firm’s Baltimore office. He has more than 16 years of experience providing tax planning and preparation and management advisory services for his clients. Mike focuses on advising privately held businesses and their owners on effective growth and tax strategies. He also performs various engagements for mergers and acquisitions and complex cost accounting projects and projections. In addition, he represents various government contracting clients before the DCAA and assists with FAR compliance. Mike’s areas of concentration include working with government contractors, professional service firms, construction companies, and homebuilders.
  • Blog Posts
    Powering the Future Maximizing Energy Storage Value with David Braun
    In this episode of the MSSIA Insight Podcast, host Matthew Karmel, Chair of Offit Kurman’s Environmental & Sustainability Practice, sits down with David Braun, Chief Commercial Officer at Intelligent Generation, to explore how distributed energy storage is creating new opportunities for businesses, developers, and the broader energy grid.With more than 35 years of experience in the energy and utility sector, David shares how battery storage can help commercial and industrial customers earn revenue, reduce energy costs, and improve power reliability. The conversation explores revenue stacking, including how batteries can generate value through wholesale energy markets, reduce capacity and transmission charges, store excess solar energy, and provide backup power during outages or disruptions.Matthew and David also discuss the evolving energy storage landscape across New Jersey, Pennsylvania, and Delaware, highlighting differences in state policies, utility programs, and opportunities for virtual power plants. David explains how industry collaboration through MSSIA can help advance effective energy policies and accelerate project development.Looking ahead, David shares his perspective on the future of distributed energy storage, the transition toward a more interconnected and resilient grid, and the importance of accurately modeling battery economics to demonstrate project value and support investment decisions. In this episode, you’ll learn about: How battery storage can help businesses earn revenue, save money, and protect operations. What revenue stacking means and how multiple battery applications create economic value. How rising capacity and transmission charges are influencing energy storage opportunities in PJM. The differences in energy storage policies and incentives across New Jersey, Pennsylvania, and Delaware. The role of virtual power plants in supporting grid reliability and managing energy demand. Why accurate financial modeling, customer load profiles, and utility rate structures are critical to evaluating battery projects. How MSSIA supports industry collaboration and policy advocacy across the Mid-Atlantic. Whether you're a solar or storage developer, investor, contractor, attorney, or clean energy professional, this episode offers practical insights into the economics, policy considerations, and emerging opportunities shaping the distributed energy storage market. About the MSSIA Insight Podcast Powered by Offit Kurman and presented in partnership with the Mid-Atlantic Solar & Storage Industries Association (MSSIA), the MSSIA Insight Podcast explores the legal, regulatory, and business developments shaping the solar and energy storage industries across New Jersey, Pennsylvania, and Delaware. Hosted by Matthew Karmel, the podcast features conversations with industry leaders and subject matter experts, delivering actionable insights to help clean energy professionals navigate an evolving industry. New episodes are released every other month.   Join our next policy committee call as a guest to see firsthand the impact we're driving: https://forms.gle/8WqmDvdJUKBh35Qw7
  • Events
    AIA Tri-State Conference
    Princeton will serve as the backdrop for three days of connection, learning, and design leadership. From keynotes to tours to the Tri-State Design Awards, this year’s conference is designed to go far beyond education sessions. Kick off the week with pre-conference intensives and individual state component Design Award celebrations, followed by three days of education, inspiration, networking, and design excellence at the 2026 AIA Tri-State Conference—featuring pre-conference intensives, three keynote speakers, 25 education sessions, curated tours, an expo, spec academies, and the AIA Tri-State Design Awards—bringing together architects and design professionals from New Jersey, New York, and Pennsylvania to connect, learn, and celebrate the best of the profession. G2. Designing Secure Practices: Cybersecurity, Data Privacy, Contractual Provisions, and Insurance Risks for Architects (4:00 PM - 5:30 PM) Architects and design professionals increasingly rely on cloud platforms, BIM software, and digital tools to manage sensitive data, creating cybersecurity and privacy risks. A single incident can trigger liability claims, regulatory obligations, reputational harm, and insurance challenges. Yet many firms underestimate how contracts, insurance, and internal practices intersect during a breach. This program offers legal and insurance perspectives on cyber risk in architecture, examining liability exposure, risky contract provisions, and mitigation strategies. A cyber insurance expert will explain policy responses, coverage gaps, coordination with professional liability, and best practices for aligning insurance with contractual risk and protecting firms from evolving cyber threats. Learning Objectives: Identify key cybersecurity and data privacy risks faced by architecture firms and explain how these risks can impact professional liability and project outcomes. Analyze common contractual provisions to determine which clauses may increase exposure to cyber incidents and propose strategies to mitigate these risks. Evaluate the scope and limitations of cyber insurance policies, including coordination with professional liability coverage, to determine how a policy would respond in a breach scenario. Develop actionable risk management strategies by integrating legal, contractual, and insurance considerations to protect sensitive client and project data.